What the pathology report needs to establish
A pathology report is not one page. For non-small cell lung cancer it normally contains a histological type, a specimen description, and information about how the sample was obtained. The distinction between a biopsy, a resection specimen and a cytology sample matters because it affects how much material remains for further testing. If the report does not state the specimen type clearly, that is a question for the reviewing pathologist, not something to assume.
The report may also describe grade, lymphovascular or pleural involvement, and margin status where a resection has been performed. These are descriptive findings. They do not by themselves tell a patient which treatment is appropriate, and they should not be read as a treatment recommendation. A lung lobectomy removes a lung lobe and is different from removal of an entire lung, so if surgery has already happened, the operative and pathology documents should be read together rather than in isolation.
For an overseas review, the practical issue is legibility and completeness. A scanned report with cut-off margins, missing pages or untranslated blocks creates avoidable delay. Ask the original hospital for a complete copy including addenda, because addenda often contain the molecular results that were issued after the initial report.
Biomarker results: what to send and what to ask
Biomarker testing in non-small cell lung cancer can include EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, HER2 and PD-L1, depending on the case and the testing platform used. The exact panel is a clinical decision, so this article does not recommend which markers a patient should have tested. What matters for a review is that the actual result reports are sent, not a summary line in a discharge letter.
Each result should be traceable to a method. A next-generation sequencing report, a single-gene assay and an immunohistochemistry result are different documents with different limitations. If the report states a variant, it should also state the assay, the specimen used and whether the result was adequate. A result described only as positive or negative without a method is difficult for a receiving team to interpret.
PD-L1 reporting is a common source of confusion because it is usually expressed as a score or percentage with a named assay. A number without the assay name cannot be compared with another laboratory's result. If the original report does not name the assay, ask the testing laboratory to issue a clarification rather than guessing.
Previous cancer therapy changes what the review needs
If the patient has already received systemic therapy, targeted therapy or immunotherapy, the review needs a treatment chronology. This is not a full medical archive. It is a dated list of what was given, when it started and stopped, and why it changed. A receiving clinician uses this to understand what has already been tried and what the current question actually is.
The same applies to prior surgery and radiotherapy. A short summary with dates and treating hospital names is more useful than a folder of unrelated invoices. If a prior treatment was stopped because of toxicity, that reason belongs in the summary. If it was stopped because of progression, that also belongs there. The distinction changes how a new team reads the case.
Do not send a complete archive at first contact. A brief summary with the main question allows the team to identify which records are actually needed. Passport numbers, payment details and full imaging files are not required for an initial enquiry.
Local and systemic options: what a records review can and cannot settle
A records-based opinion can discuss whether the available pathology and biomarker information is sufficient to consider local therapy, systemic therapy or both. It cannot confirm hospital acceptance, final eligibility or treatment availability. Those decisions belong to the treating hospital and licensed clinicians after they have seen the patient and the original materials.
This distinction matters because patients sometimes treat a remote opinion as a booking. It is not. A remote review is a way to understand the case and prepare questions. It does not replace an in-person assessment, and it does not establish that a particular drug, trial or procedure is available in China.
If the question is whether surgery remains possible, the review needs imaging and operative records as well as pathology. If the question is about systemic therapy, the biomarker reports and treatment history carry more weight. Sending the right documents for the actual question is more useful than sending everything.
Preparing the report set for a China review
Organise the documents by type and date. A single PDF with a contents page is easier to work with than a dozen separate photographs. Label each file clearly, for example pathology report, biomarker report, imaging report, treatment summary. This is administrative preparation, not clinical interpretation.
Check that the pathology and biomarker reports are the final versions, including addenda. If a report was amended, send the amendment. If a test was repeated at a different laboratory, send both results so the receiving team can see the sequence.
Translation is a practical question to confirm with the specific hospital or coordination team. Do not assume that English reports will be accepted without any translation, and do not assume that a translation must be certified in a particular way. Ask what the receiving provider actually requires for the route being used.
A useful report set is not the same as a complete archive. The receiving clinician needs the documents that answer the current question, not every record the patient has ever received. If the question is whether surgery remains possible, imaging and operative records matter more than a full medication list. If the question is about systemic therapy, biomarker reports and the treatment chronology carry the weight.
Keep a one-page cover sheet at the front. It should state the diagnosis, the date of diagnosis, the specimen type, the biomarker results with assay names, and the specific question the patient wants answered. This sheet is a navigation aid for the reviewing team, not a clinical summary written by the patient.
If a document is missing, say so on the cover sheet rather than leaving the reviewer to discover the gap. A missing pathology addendum or an absent PD-L1 assay name is easier to resolve before the review starts than after a question has been raised.
Do not send original documents by post. Keep the originals and send clear scans. If a report is only available as a photograph, check that the text is readable before sending it. A blurred image of a biomarker result is not useful to anyone.
- A dated list of prior cancer therapy, including reason for stopping.
- Final pathology report with any addenda.
- Biomarker reports showing assay name and specimen used.
- Imaging reports relevant to the current question.
- A short written statement of the patient's main question.
What to confirm before travelling
Before any travel, confirm in writing what the receiving hospital has agreed to review, what it still needs, and whether an in-person visit is expected. Ask whether the hospital will repeat any pathology or biomarker testing, because a repeat test may change the report set and the timeline. Do not assume that existing results will be accepted unchanged.
Ask who will explain the results and in what language. Ask what the written plan will include and what remains to be decided after the visit. These are provider-specific questions, and the answers should come from the hospital or the coordination team handling the case, not from a general guide.
Urgent or worsening symptoms need local assessment first. An overseas enquiry should not delay necessary care. If the patient is stable and the question is about reviewing existing reports, an initial enquiry can start with a brief summary and the main question. The hospital decides suitability, and a remote review does not establish trial enrolment, transplant access or therapy availability.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.